The decision to perform combined kidney/liver
|
|
- Sophia Merritt
- 6 years ago
- Views:
Transcription
1 ORIGINAL ARTICLES Renal Function after Orthotopic Liver Transplantation is Predicted by Duration of Pretransplantation Creatinine Elevation Mical S. Campbell, 1 David S. Kotlyar, 2 Colleen M. Brensinger, 3 James D. Lewis, 1,3 Kirti Shetty, 4 Roy D. Bloom, 5 James F. Markmann, 6 Kim M. Olthoff, 6 Abraham Shaked, 6 and K. Rajender Reddy 1 See Editorial on Page 1022 Abbreviations: CKLT, combined kidney/liver transplantation; OLTa, orthotopic liver transplantation alone; OLT, orthotopic liver transplantation; MELD, model for end-stage liver disease; HRS, hepatorenal syndrome; RRT, renal replacement therapy; ROC, receiver operating characteristic. From the 1 Division of Gastroenterology, University of Pennsylvania Health System, Philadelphia, PA; the 2 University of Pennsylvania School of Medicine; the 3 Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania; the 4 Division of Gastroenterology, Georgetown University Hospital; the 5 Department of Nephrology, University of Pennsylvania Health System; and the 6 Division of Surgery, University of Pennsylvania Health System. Received February 25, 2005; accepted March 7, Address reprint requests to K. Rajender Reddy, MD, Hospital of the University of Pennsylvania, Division of Gastroenterology, 3 Ravdin, 3400 Spruce St., Philadelphia, PA Telephone: ; FAX: ; rajender.reddy@uphs.upenn.edu Copyright 2005 by the American Association for the Study of Liver Diseases Published online in Wiley InterScience ( DOI /lt In patients with recent onset renal insufficiency, the decision to perform combined kidney/liver transplantation (CKLT) vs. orthotopic liver transplantation alone (OLTa) can be difficult. We hypothesized that duration of renal dysfunction may correlate with creatinine elevation after liver transplantation. We retrospectively identified 69 liver transplantation patients with pretransplantation creatinine >1.5 mg/dl (53 OLTa, 13 CKLT). Variables analyzed were presence of hepatorenal syndrome, creatinine, Model for End-Stage Liver Disease score, albumin, age, race, gender, cause of liver disease, diabetes mellitus, hypertension, and history of ascites, spontaneous bacterial peritonitis, variceal bleeding, hepatic encephalopathy, renal replacement therapy (RRT), and transjugular intrahepatic portosystemic shunting. Duration of pretransplantation renal dysfunction was predictive of 6- and 12-month creatinine post-olta. Area under the receiver operating characteristic (ROC) curve for prediction of 12-month renal insufficiency by renal dysfunction duration was 0.71; optimal duration cutoff was 3.6 weeks. We applied a multivariable model, derived from OLTa patients, to CKLT subjects with definite or possible hepatorenal syndrome. Predicted 12-month creatinine without renal transplantation was >2.0 mg/dl for each patient. CKLT patients as opposed to OLTa patients had longer duration of renal dysfunction (median, 18.1 vs. 2.7 weeks, P < 0.001), higher creatinine (median 4.0 versus 1.7 mg/dl, P < 0.001), and higher rate of pretransplantation RRT (62% vs. 7%, P < 0.001). Adjusting for baseline characteristics, CKLT patients had lower creatinine than OLTa patients at 6 months (P 0.15) and 12 months (P 0.01) after transplantation. In conclusion, duration, but not cause, of renal dysfunction predicts renal outcome in OLTa recipients. Prospective studies may use duration of renal dysfunction to help identify CKLT candidates. (Liver Transpl 2005;11: ) The decision to perform combined kidney/liver transplantation (CKLT) as opposed to orthotopic liver transplantation alone (OLTa) can be difficult in patients with end-stage liver disease and recent onset renal insufficiency. The rate of acute renal failure among patients awaiting orthotopic liver transplantation (OLT) and the waiting time for OLT have increased in recent years. 1 The recent introduction of the Model for End-Stage Liver Disease (MELD) score will likely further enrich the proportion of OLT candidates who have renal dysfunction, as creatinine is a key component of MELD calculation. Because of scarce organ resources, it is important to predict accurately which patients with pretransplantation renal dysfunction will recover after OLT and who will have persistent or progressive kidney disease. Pretransplantation serum creatinine level is an important predictor of post-olt survival and renal dysfunction. 2-7 Even relatively mild elevations in preoperative creatinine ( mg/dl) may portend poor renal function postoperatively. 5-7 Cause of renal disease may also help predict posttransplantation creatinine. Certainly patients with underlying chronic kidney diseases such as glomerulonephritis, diabetic nephropathy, and polycystic kidney disease would be expected to have persistently poor or worsening renal function after OLTa, particularly in the setting of cal Liver Transplantation, Vol 11, No 9 (September), 2005: pp
2 Duration of Renal Dysfunction and OLT 1049 cineurin inhibitor based immunosuppression. Many transplant centers have reported that a large majority of their CKLT patients underwent transplantation for chronic kidney disease In contrast, studies from the early 1990s demonstrate that patients with hepatorenal syndrome (HRS) have a good post-olta renal outcome 14,15 and may avoid concomitant renal transplantation. Because waiting times for liver transplantation and duration of renal dysfunction prior to transplantation have increased since then, 16 it is possible that renal outcomes after OLTa in patients with HRS may be less favorable now. Recommendations from a recent review emphasize that cause and severity of renal disease should guide the decision to perform CKLT as opposed to OLTa. Furthermore, the authors suggest that in the absence of parenchymal renal disease, patients with duration of renal dysfunction 12 weeks will likely recover renal function and should not undergo CKLT. 16 However, data to support the premise that duration of pretransplantation renal dysfunction is an important predictor of post-olt renal function are not available. We performed our study to determine the association between duration of preoperative creatinine elevation and posttransplantation renal function. Patients and Methods Study Design We identified a retrospective cohort of 69 patients who underwent OLT between March 2000 and August 2003 at the Hospital of the University of Pennsylvania with renal dysfunction. Only patients with 2 serum creatinine values 1.5 mg/dl were included in the study. The database is a prospectively maintained repository of all clinical information related to liver transplantation patients seen at our institution and is well-suited to rigorous investigations. Six months to 4 years of follow-up laboratory and clinical information are available for all patients included in the study. Subjects who had previously undergone liver transplantation or who had fulminant hepatic failure were not included. Thirteen of 69 patients underwent CKLT. Institutional Review Board approval was obtained before the study was conducted. Our institution is a large liver transplantation center, performing liver transplantations per year. Patients included in the study were transplanted before and after the introduction of MELD score (February 27, 2002). Patients with renal disease were evaluated by our center s transplant nephrologists. The decision to perform CKLT vs. OLTa was made on a case-by-case basis. Factors that influenced the recommendation for CKLT included cause, duration, and severity of renal disease, as well as requirement for renal replacement therapy (RRT). All serum creatinine values before transplantation were obtained, starting with the first creatinine 1.5 mg/dl. Duration of renal dysfunction is defined as the number of weeks before transplantation during which creatinine was persistently 1.5 mg/dl, including the last creatinine prior to transplantation. Cause of renal disease was agreed upon for each patient by 3 investigators (M.S.C., D.S.K., and K.R.R.) and was classified as HRS, not HRS, or uncertain. Data used for classification of renal disease, obtained from both inpatient and outpatient records, include urine sodium, urinalysis, 24-hour urine volume, presence or absence of diuretics, response to intravenous fluid challenge, renal biopsy (if available), and pattern of changes in creatinine. Underlying conditions associated with chronic kidney disease, such as diabetes mellitus and hypertension, as well as exposure to acute insults such as intravenous contrast agents, nephrotoxic drugs, diuretics, and sepsis were also reviewed. Diagnosis of HRS was guided by International Ascites Club recommendations: presence of advanced liver disease, serum creatinine 1.5 mg/dl, absence of concurrent explanations for renal insufficiency, failure of response to volume expansion, and absence of proteinuria or other evidence for parenchymal renal disease, with additional criteria of low urine volume, low urine sodium, low serum sodium, urine osmolality plasma osmolality, and absence of red blood cells on urinalysis. 17 Patients with HRS were not subdivided into types 1 and 2 because the principal distinction between the 2 groups is duration of renal dysfunction, a variable analyzed separately. Other variables include presence of diabetes mellitus, hypertension, and hepatocellular carcinoma, cause of liver disease, age, race, gender, requirement for RRT prior to OLT, last serum creatinine prior to transplantation, MELD score, serum albumin, international normalized ratio, bilirubin, and history of ascites, spontaneous bacterial peritonitis, variceal bleeding, hepatic encephalopathy, transjugular intrahepatic portosystemic shunt placement, and type of immunosuppression given post-olt. Laboratory values closest in time to transplantation were used. Primary outcomes were serum creatinine values at 6 and 12 months posttransplantation. Secondary outcomes were requirement for RRT at any time post-olt and continuing RRT requirement at 6 and 12 months post-olt. Statistical Methods Means and standard deviations are reported for parametric variables. For nonnormally distributed variables, medians and quartiles are given. Wilcoxon rank sum tests, ANOVA, Fisher exact tests, and unpaired t tests were used to compare variables between groups undergoing OLTa and CKLT. Univariate and multivariate linear regression were performed for OLTa patients, forcing duration of pretransplant renal disease into multivariate models. A multivariable model including all patients was generated, forcing the treatment group (CKLT vs. OLTa) into the model. Pre-OLT creatinine could not be included in this model because it was collinear with the treatment group. Nonparametric variables were first transformed
3 1050 Campbell et al. Table 1. Baseline Characteristics of OLTa and CKLT Patients Variable OLTa (n 53) Mean Standard Deviation, n (%), or Median (Interquartile Range) CKLT (n 13) Mean Standard Deviation, n (%), or Median (Interquartile Range) P Value Age years years 0.40 Gender 45 (80%) male 11 (85%) male 1.00 Race 50 (89%) white 9 (69%) white 0.08 Required RRT 4 (7%) 8 (62%) Diabetes mellitus 15 (27%) 6 (50%) 0.17 Hypertension 20 (36%) 5 (42%) 0.75 Cause of renal disease 0.83 HRS 15 (27%) 2 (15%) Not HRS 32 (57%) 9 (69%) Uncertain 9 (16%) 2 (15%) Cause of liver disease 0.09 Viral 28 (50%) 6 (46%) NASH 12 (21%) 0 (0%) Alcohol 8 (14%) 2 (15%) Other 8 (14%) 5 (38%) Hepatocellular carcinoma present 10 (18%) 4 (31%) 0.44 Ascites 55 (98%) 12 (92%) 0.34 Hepatic encephalopathy 46 (82%) 9 (69%) 0.44 History of spontaneous bacterial peritonitis 21 (38%) 3 (23%) 0.52 History of variceal bleeding 14 (25%) 0 (0%) 0.06 TIPS placement 7 (12.5%) 3 (23%) 0.38 MELD Albumin 2.5 mg/dl ( mg/dl) 2.3 mg/dl ( mg/dl) 0.82 Pretransplant creatinine 1.7 mg/dl ( mg/dl) 4.0 mg/dl ( mg/dl) INR 1.9 ( ) 1.5 ( ) 0.26 Bilirubin 3.1 mg/dl ( mg/dl) 1.4 mg/dl ( mg/dl) 0.06 Duration of pretransplant renal disease 2.7 weeks ( weeks) 18.1 weeks ( weeks) Abbreviations: NASH, nonalcoholic steatohepatitis; TIPS, transjugular intrahepatic portosystemic shunt; INR, international normalized ratio. (logarithmic transformation for duration of renal disease, international normalized ratio, and bilirubin; reciprocal transformation for creatinine) before linear regression was performed. Multivariable linear regression models were generated by stepwise backward elimination, using a P value greater than 0.05 to remove variables not significantly associated with outcome. All univariate variables with P values 0.20 were considered for multivariate analysis. A receiver operating characteristic (ROC) curve was generated for prediction of 12-month creatinine 1.5 mg/dl by natural logarithm of duration of renal disease among OLTa patients. Statistical programs used were SAS 8.2 (SAS Institute, Cary, NC) and Stata 8.1 (Stata Corp, College Station, TX). A P value 0.05 is considered significant. Results We identified 56 patients with pretransplant renal dysfunction who underwent OLTa and 13 subjects who received CKLT (Table 1). Among OLTa patients, 15 (27%) had diabetes mellitus, 20 (36%) had hypertension, and 15 (27%) were diagnosed with hepatorenal syndrome. Thirty-two (57%) of OLTa patients did not have HRS. Causes for renal dysfunction (more than 1 identified in 3 subjects) among non-hrs OLTa patients were diuretics (19), acute tubular necrosis (8), glomerulonephritis (2), infection (2), volume depletion (1), hypotension (1), and unknown (2). Mean MELD was Of 34 patients with viral hepatitis, 7 had both hepatitis C and alcohol-related liver disease. Thirteen patients had other causes of liver disease: autoimmune hepatitis (n 3), alpha-1 antitrypsin disease (n 3), hemochromatosis (n 2), Budd-Chiari syndrome (n 2), veno-occlusive disease (n 1), cystic fibrosis (n 1), and polycystic liver disease (n 1). Patients undergoing CKLT as opposed to OLTa had longer duration of pretransplant renal dysfunction (median 18.1 vs. 2.7 weeks, P 0.001). Seventy-five
4 Duration of Renal Dysfunction and OLT 1051 Table 2. Post-OLT Characteristics of OLTa and CKLT Patients Variable OLTa (n 56) n (%) or Median (Interquartile Range) CKLT (n 13) n (%) or Median (Interquartile Range) P Value Cyclosporine use 0 (0%) 0 (0%) Tacrolimus use 51 (91%) 13 (100%) 0.58 Sirolimus use 14 (25%) 2 (15%) month creatinine 1.4 mg/dl ( mg/dL) 1.6 mg/dl ( mg/dL) month creatinine 1.4 mg/dl ( mg/dL) 1.5 mg/dl ( mg/dL) 0.97 RRT ever post-olt 13 (23%) 2 (15%) 0.72 RRT at 6 months 0 (0%) 0 (0%) RRT at 12 months 1 (2%) 0 (0%) percent of OLTa patients had a duration of pretransplant renal dysfunction less than 6.4 weeks, whereas 75% of CKLT patients had elevated creatinine levels for longer than 8.0 weeks. CKLT patients, as opposed to OLTa patients, also had higher serum creatinine (median, 4.0 vs 1.7 mg/dl, P 0.001), and were more likely to have received RRT (62% vs. 7%, P 0.001) before transplantation. RRT in each case was hemodialysis. Duration of RRT for the 4 OLTa patients was 0.14, 0.57, 0.71, and 1.43 weeks. Eight CKLT patients required RRT for a median of 7.6 weeks (range, weeks), P compared to OLTa. Subjects were otherwise similar between the 2 groups. CKLT patients had similar post-olt creatinine compared to OLTa patients, and only one person required RRT by 12-month follow-up (Table 2). Patients were selected for CKLT because transplant nephrologists felt recovery of renal function after OLTa would be unlikely (Table 3). In 3 cases, the primary reason for CKLT was a relatively long duration of acute renal insufficiency. Only 3 patients had end-stage renal disease requiring more than 9 weeks of RRT prior to transplantation (Table 3). We documented biopsy results in 2 subjects (patients 4 and 9). Duration of pretransplant renal disease was a significant predictor of post-olta creatinine (Tables 4 and 5). Multivariate analysis showed that both duration of pretransplant renal disease (P 0.002) and other Table 3. Characteristics of CKLT Patients Patient Reason for CKLT Duration of Renal Disease (weeks) Duration of RRT, If Required (weeks) 1 Long duration of possible HRS End-stage hypertensive nephropathy Multifactorial renal insufficiency and planned nephrectomy 12.4 N/A for renal cell carcinoma at time of transplant 4 Membranoproliferative glomerulopathy 32.3 N/A 5 Long duration of HRS and chronic renal insufficiency Long duration of HRS Multifactorial renal insufficiency and planned nephrectomy for renal cell carcinoma at time of transplant 8 Membranoproliferative glomerulonephritis and diabetic glomerulopathy 9 Membranoproliferative glomerulonephritis 3.4 N/A 10 Polycystic kidney disease Acute renal failure induced by diuretics and uncertain cause 18.1 N/A chronic renal insufficiency 12 NSAID nephropathy 6.1 N/A 13 Lupus nephritis and cyclosporine toxicity Abbreviations: N/A, not applicable; NSAID, nonsteroidal antiinflammatory drug.
5 1052 Campbell et al. Table 4. Predictors of Serum Creatinine 6 Months After OLTa Univariate Analysis Duration of pretransplant renal disease ( )* 0.04 Multivariate Analysis Duration of pretransplant renal disease ( )* Cause of liver disease (compared to other) Viral 0.32 ( ) NASH 0.30 ( ) 0.01 Alcohol 0.39 ( ) Abbreviation: NASH, nonalcoholic steatohepatitis. *Inverse creatinine (mg/dl) per natural logarithm of duration (weeks). Inverse creatinine (mg/dl). cause of liver disease (P 0.01) predicted 6-month post-olta creatinine (Table 4). Pretransplantation creatinine (P 0.001) and bilirubin (P 0.006) were significant predictors of post-olta creatinine at 12 months (Table 5). All other variables analyzed were not associated with post-olta creatinine. We performed ROC analysis for prediction of creatinine 1.5 mg/dl at 12 months after OLTa (Fig. 1). Area under the ROC curve was Using duration of 3.6 weeks as a test threshold, sensitivity was 62.5% with specificity 69.2%, positive predictive value 71.4%, and negative predictive value 60.0%. Our formula for prediction of creatinine (mg/dl) 12 months after OLTa is: 1/(.8595 [1/pretransplant creatinine (mg/dl)] ln[bilirubin (mg/ dl)] ln[duration of renal insufficiency (weeks)] ), (model R , adjusted R ). For example, a patient with 8 weeks duration of renal insufficiency, creatinine 3.0 mg/dl, and bilirubin 5.0 mg/dl would be expected to have a creatinine of 2.0 mg/dl post-olta. We applied this model, derived from OLTa patients, to the 4 CKLT subjects with possible or definite HRS. Predicted 12-month creatinine in the absence of concomitant renal transplanta- Table 5. Predictors of Serum Creatinine 12 Months After OLTa Univariate Analysis Duration of pretransplant renal disease ( )* 0.01 Diabetes mellitus 3.21 ( )* Pretransplant creatinine 0.48 ( ) 0.01 Bilirubin ( ) 0.02 INR 0.22 ( ) 0.02 Multivariate Analysis Duration of pretransplant renal disease ( )* 0.10 Pretransplant creatinine 0.86 ( ) Bilirubin ( ) Abbreviation: INR, international normalized ratio. *Inverse creatinine (mg/dl) per natural logarithm of duration (weeks). Inverse creatinine post-olta (mg/dl) per inverse creatinine pre-olta (mg/dl). Inverse creatinine (mg/dl) per natural logarithm of bilirubin (mg/dl). Inverse creatinine (mg/dl) per natural logarithm of INR.
6 Duration of Renal Dysfunction and OLT 1053 Figure 1. ROC curve for duration of pre-olta renal dysfunction predicting creatinine >1.5 mg/dl 12 months post-olta. Each dot represents a different test threshold. tion was 2.0 mg/dl for all 4 patients (range, mg/dl). Predictors of posttransplantation creatinine were assessed among all patients, forcing the transplantation group (CKLT vs. OLTa) into the multivariate analysis (Table 6). Duration of pretransplant renal disease was a significant predictor of both 6- and 12-month post-transplantation creatinine (P 0.02, P 0.003). After adjusting for duration of pretransplant renal disease and other baseline characteristics, CKLT was associated with significantly lower creatinine at 12 months compared to OLTa. Discussion These data suggest that duration of pretransplant renal dysfunction is an independent predictor of renal function after OLTa. Interestingly, presence or absence of HRS was not associated with post-olta renal outcomes. It has long been recognized that preexisting chronic kidney disease is an important indication for CKLT because pretransplant renal function will not improve post-olta In contrast, HRS has generally portended a better renal prognosis after OLTa. 14,15 However, duration of pretransplant renal dysfunction is an important confounding variable that has not been studied. It is possible that previous studies have demonstrated better renal outcomes for HRS patients because those patients had the shortest durations of renal dysfunction prior to transplantation. Our study suggests that duration, not cause, of pretransplant renal dysfunction is key to predicting creatinine after transplantation. A thorough effort was made in our study to accurately diagnose HRS. Three investigators reviewed all available data and agreed on a renal diagnosis for each patient, following International Ascites Club guidelines. 17 Only 27% of OLTa patients were diagnosed with HRS. It is possible that some cases categorized as other or unknown in fact represented HRS. HRS can be difficult to diagnose and requires exclusion of other causes. Misclassification bias is unlikely to affect our results, because we introduced a third category for cases in which HRS could not be ruled definitively in or out. HRS can be divided into types 1 and 2, principally by the rate at which renal dysfunction progresses. We did not distinguish between types 1 and 2, because our duration of renal dysfunction variable makes such a Table 6. Predictors of Serum Creatinine After Transplantation, Adjusting CKLT vs. OLTa by Baseline Characteristics Creatinine 6 Months Post-OLT CKLT (instead of OLTa) 0.12 ( )* 0.15 Duration of pretransplant renal disease ( ) 0.02 Cause of liver disease (compared to other) Viral 0.20 ( )* 0.02 NASH 0.23 ( )* 0.04 Alcohol 0.28 ( )* 0.01 White race (vs. other) 0.20 ( )* 0.02 Creatinine at 12 Months Post-OLT CKLT (instead of OLTa) 0.21 ( )* 0.01 Duration of pretransplant renal disease ( ) White race (vs. other) 0.28 ( )* RRT pretransplantation 0.19 ( )* 0.03 Abbreviation: NASH, nonalcoholic steatohepatitis. *Inverse creatinine (mg/dl). Inverse creatinine (mg/dl) per natural logarithm of duration (weeks).
7 1054 Campbell et al. distinction redundant. One possible explanation for our results could be that type 1 HRS (shorter duration of renal dysfunction) portends better posttransplantation renal function than type 2 (longer duration of renal dysfunction). Clinically, it is often quite challenging to distinguish HRS from other conditions associated with effective volume contraction. Furthermore, renal dysfunction may be multifactorial. Therefore, duration may be a more user-friendly clinical variable. We chose a creatinine cutoff of 1.5 mg/dl for inclusion in the study. Such a creatinine value is the minimum required to diagnose HRS. 17 Other studies have used the same or lower creatinine cutoffs to define pretransplant renal dysfunction. 5-7 In a patient with endstage liver disease, a creatinine of 1.5 mg/dl signifies more advanced renal impairment than in a patient without liver disease. Cirrhotics have decreased synthesis of creatinine, decreased muscle mass, hyperbilirubinemia, and volume expansion. 16 Formulas such as the Cockcrot-Gault equation and the Modification of Diet in Renal Disease formula use creatinine, age, serum albumin, serum blood urea nitrogen, and/or body weight to estimate glomerular filtration rate. Neither these formulas nor calculation of creatinine clearance from a 24-hour urine collection has been well studied or validated in patients with decompensated cirrhosis. 17 Ideally, renal function can be estimated through the use of inulin, [ 125 I]iothalamate, or 51Cr-EDTA clearance methods, though this is costly and often impractical. After transplantation, only one patient developed end stage renal disease requiring continuing RRT. However, one-half of patients had serum creatinine higher than 1.5 mg/dl, regardless of whether or not they had received a concomitant kidney with a liver. Even moderate renal insufficiency in posttransplantation patients can be significant, because renal dysfunction after transplantation may be progressive, in part because of nephrotoxic immunosuppression regimens, development of hypertension, and diabetes mellitus. Short-term renal dysfunction after transplantation has been associated with long-term poorer prognosis. 1,18 Predictive variables other than duration of pretransplant renal dysfunction were identified. Preoperative serum creatinine and diabetes mellitus are well-known risk factors for the development of renal dysfunction. Multivariable analysis of OLTa patients showed bilirubin and creatinine, 2 components of MELD, were predictive of 12-month creatinine. A prior study identified MELD as a variable associated with postoperative renal dysfunction, similar to our result. 19 Other variables found to be associated with worse post-olt renal function were white race and other cause of liver disease. Both of these findings could potentially be artifactual, given the relatively small numbers of patients who were nonwhite and who had other cause of liver disease. Only 1 patient had polycystic liver disease. Patients undergoing CKLT as opposed to OLTa were different in several key respects. CKLT patients had longer duration of pretransplant renal dysfunction (median, 18.1 vs. 2.7 weeks), higher serum creatinine, and increased requirement for RRT preoperatively. Whereas 75% of OLTa patients had pretransplant renal dysfunction for less than 6.4 weeks, 75% of CKLT patients had elevated creatinine lasting over 8.0 weeks. Postoperatively, the 2 groups of patients were exposed to similar rates of cyclosporine, tacrolimus, and sirolimus usage. Serum creatinine values at 6 and 12 months were also similar between CKLT and OLTa patients. After adjusting for baseline characteristics (including duration of pretransplant renal disease), CKLT patients had better renal function at 12 months (statistical significance not reached at 6 months). These data suggest that in our study population, patients with features predictive of poor renal function after liver transplantation were appropriately selected for CKLT. ROC analysis among OLTa patients showed that duration of renal disease by itself had a moderate ability to predict creatinine 1.5 mg/dl at 12 months posttransplantation (area under ROC curve 0.71). The optimal predictive cutoff was 3.6 weeks. It is noteworthy that all but 1 CKLT patient did have duration of renal disease 3.6 weeks (1 CKLT patient had 3.4 weeks of renal insufficiency). However, we cannot at this time recommend that all patients with duration of renal disease longer than 3.6 weeks undergo CKLT. A creatinine of 1.5 mg/dl 1 year after transplantation is not necessarily high enough to justify concomitant renal transplantation. Instead, long-term studies are needed to determine what creatinine can be tolerated at 1 year post-olta before renal failure becomes likely over the next several years. Because 75% of our OLTa patients had creatinine 1.9 mg/dl or less at 12 months post-olta, we could not perform ROC analyses for higher creatinine outcomes. Furthermore, our area under the ROC curve is not high enough to justify use of duration of renal disease in isolation. Instead, other predictive features, such as height of creatinine and requirement for RRT, may be considered in combination with the duration of renal disease to predict post- OLTa renal function. We applied our multivariable model, derived from OLTa patients, to predict 12-month creatinine posttransplantation in the 4 CKLT subjects with definite or possible HRS. In the absence of renal transplantation,
8 Duration of Renal Dysfunction and OLT 1055 all 4 CKLT patients would have expected creatinine 2.0 mg/dl 12 months post-olta. Although we cannot definitively state how high a 1-year posttransplantation creatinine can be tolerated before CKLT should be performed, a creatinine value in the range of 2-3 mg/dl seems reasonable. In summary, our data suggest that duration of pretransplant renal dysfunction may help identify those patients most in need of CKLT as opposed to OLTa. A threshold duration of renal dysfunction in combination with other clinical variables may be prospectively investigated as an aid to clinical decisionmaking. Acknowledgment The authors thank Mary Kaminski of the Department of Surgery, University of Pennsylvania Health System, for her contributions to this study. References 1. Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, et al. Renal replacement therapy (RRT) and orthotopic liver transplantation (OLTX): The role of continuous veno-venous hemodialysis. Transplantation 2001;71: Nair S, Verma S, Thuluvath PJ. Pretansplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002;35: Markmann JF, Markmann JW, Markmann DA, Bacquerizo A, Singer J, Holt CD, et al. Preoperative factors associated with outcome and their impact on resource use in 1148 consecutive primary liver transplants. Transplantation 2001;72: Brown RS, Lombardero M, Lake JR. Outcome of patients with renal insufficiency undergoing liver or liver-kidney transplantation. Transplantation 1996;62: Bilbao I, Charco R, Balsells J, Lazaro JL, Hildalgo E, Llopart L, et al. Risk factors for acute renal failure requiring dialysis after liver transplantation. Clin Transplant 1998; 12: Lafayette RA, Pare G, Schmid CH, King AJ, Rohrer RJ, Nasraway SA. Pretransplant renal dysfunction predicts poorer outcome in liver transplantation. Clin Nephrol 1997;48: Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 2003;9: Margreiter R, Konigsrainer A, Spechtenhauser B, Ladurner R, Pomarolli A, Hormann Ch, et al. Our experience with combined liver-kidney transplantation: An update. Transplant Proc 2002; 34: Lang M, Neumann U, Kahl A, Steinmuller T, Settmacher U, Neuhas P. Long-term outcome of 27 patients after combined liver-kidney transplantation. Transplant Proc 2001;33: Ammor M, Creput C, Durrbach A, Samuel D, Von Ey, F, Hiesse C, et al. Mortality and long term outcome of combined liver and kidney transplantations. Transplant Proc 2001;33: Gatti S, Arru M, Reggiani P, Rossi G, Tarantino A, Berardinelli L, et al. Combined liver and kidney transplantation: A singlecenter experience. Transplant Proc 2002;34: Torregrosa JV, Inigo P, Navasa M, Rimola A, Grande L, Oppenheimer F. Combined liver-kidney transplantation: Our experience. Transplant Proc 1999;31: Chui AKK, DeLeon C, Rao ARN, Verran DJ, Pathania OP, McCaughan GW, et al. Single-center experience of combined liver and kidney transplantation. Transplant Proc 1998;30: Seu P, Wilkinson AH, Shaked A, Busuttil RW. The hepatorenal syndrome in liver transplant recipients. Am Surg 1991;57: Gonwa TA, Morris CA, Goldstein RM, Husberg BS, Klintmalm GM. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome experience in 300 patients. Transplantation 1991;51: Davis CL, Gonwa TA, Wilkinson AH. Identification of patients best suited for combined liver-kidney transplantation: Part II. Liver Transpl 2002;8: Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996;23: Velidedeoglu E, Bloom RD, Crawford MD, Desai NM, Campos L, Abt PL, et al. Early kidney dysfunction post liver transplantation predicts late chronic kidney disease. Transplantation 2004; 77: Sanchez EQ, Gonwa TA, Levy MR, Goldstein RM, Mai ML, Hays SR, et al. Preoperative and perioperative predictors of the need for renal replacement therapy after orthotopic liver transplantation. Transplantation 2004;78:
Long-term outcome of liver transplantation has. Independent Risk Factors and Natural History of Renal Dysfunction in Liver Transplant Recipients
Independent Risk Factors and Natural History of Renal Dysfunction in Liver Transplant Recipients Attaphol Pawarode, * Derek M. Fine, and Paul J. Thuluvath * Renal dysfunction is common after liver transplantation.
More informationOrgan allocation for liver transplantation: Is MELD the answer? North American experience
Organ allocation for liver transplantation: Is MELD the answer? North American experience Douglas M. Heuman, MD Virginia Commonwealth University Richmond, VA, USA March 1998: US Department of Health and
More informationHepatorenal Syndrome: a Proposal for Kidney After Liver Transplantation (KALT)
LIVER TRANSPLANTATION 13:838-843, 2007 ORIGINAL ARTICLE Hepatorenal Syndrome: a Proposal for Kidney After Liver Transplantation (KALT) Richard Ruiz, Yousri M. Barri, Linda W. Jennings, Srinath Chinnakotla,
More informationFrom the 1 Department of Transplantation, Mayo Clinic, Jacksonville, FL; 2 Baylor Regional Transplant Institute, Dallas, TX; 3 Division of
Estimation of Glomerular Filtration Rates Before and After Orthotopic Liver Transplantation: Evaluation of Current Equations Thomas A. Gonwa, 1 Linda Jennings, 2 Martin L. Mai, 1 Paul C. Stark, 3 Andrew
More informationPredictors of renal recovery in patients with pre-orthotopic liver transplant (OLT) renal dysfunction
Iglesias et al. BMC Nephrology 2013, 14:147 RESEARCH ARTICLE Open Access Predictors of renal recovery in patients with pre-orthotopic liver transplant (OLT) renal dysfunction Jose Iglesias 1,2,3*, Elliot
More informationKidney Dysfunction in the Recipients of Liver Transplants
Kidney Dysfunction in the Recipients of Liver Transplants Alan Wilkinson and Phuong-Thu Pham Key Points 1. Pretransplant kidney function is an important predictor of posttransplant kidney function. 2.
More informationCirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association
CIRRHOSIS AND PORTAL HYPERTENSION Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association WHAT IS CIRRHOSIS? What is Cirrhosis? DEFINITION OF CIRRHOSIS
More informationIn the United States, the Model for End-Stage Liver. Re-weighting the Model for End-Stage Liver Disease Score Components
GASTROENTEROLOGY 2008;135:1575 1581 Re-weighting the Model for End-Stage Liver Disease Score Components PRATIMA SHARMA,* DOUGLAS E. SCHAUBEL,, CAMELIA S. SIMA,, ROBERT M. MERION,, and ANNA S. F. LOK* *Division
More informationOutcome and natural course of renal dysfunction in liver transplant recipients with severely impaired kidney function prior to transplantation
Original Article Outcome and natural course of renal dysfunction in liver transplant recipients with severely impaired kidney function prior to transplantation United European Gastroenterology Journal
More informationORIGINAL ARTICLE. Eric F. Martin, 1 Jonathan Huang, 3 Qun Xiang, 2 John P. Klein, 2 Jasmohan Bajaj, 4 and Kia Saeian 1
LIVER TRANSPLANTATION 18:914 929, 2012 ORIGINAL ARTICLE Recipient Survival and Graft Survival are Not Diminished by Simultaneous Liver-Kidney Transplantation: An Analysis of the United Network for Organ
More informationImpact of the Etiology of Acute Kidney Injury on Outcomes Following Liver Transplantation: Acute Tubular Necrosis Versus Hepatorenal Syndrome
LIVER TRANSPLANTATION 18:539-548, 2012 ORIGINAL ARTICLE Impact of the Etiology of Acute Kidney Injury on Outcomes Following Liver Transplantation: Acute Tubular Necrosis Versus Hepatorenal Syndrome Mitra
More informationRemoving Patients from the Liver Transplant Wait List: A Survey of US Liver Transplant Programs
LIVER TRANSPLANTATION 14:303-307, 2008 ORIGINAL ARTICLE Removing Patients from the Liver Transplant Wait List: A Survey of US Liver Transplant Programs Kevin P. Charpentier 1 and Arun Mavanur 2 1 Rhode
More informationSign up to receive ATOTW weekly -
HEPATORENAL SYNDROME ANAESTHESIA TUTORIAL OF THE WEEK 240 10 TH SEPTEMBER 2011 Gerry Lynch Rotherham General Hospital Correspondence to gerry.lynch@rothgen.nhs.uk QUESTIONS Before continuing, try to answer
More informationTransplant Hepatology
Transplant Hepatology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified
More informationAscites Management. Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology
Ascites Management Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Disclosure 1. The speaker Atif Zaman, MD MPH have no relevant
More informationORIGINAL ARTICLE. Simultaneous Liver-Kidney Transplantation for Adult Recipients With Irreversible End-Stage Renal Disease
ORIGINAL ARTICLE Simultaneous Liver-Kidney Transplantation for Adult Recipients With Irreversible End-Stage Renal Disease E. Moreno-Gonzalez, MD, PhD, FACS(Hon); J. C. Meneu-Diaz, MD, PhD; I. Garcia, MD;
More informationClinical Outcomes of Renal Transplantation in Hepatitis C Virus Positive Recipients
Original Research Article Clinical Outcomes of Renal Transplantation in Hepatitis C Virus Positive Recipients Surendran Sujit 1*, N. Gopalakrishnan 2 1 Assistant Professor, 2 Professor and Head Department
More informationDialyzing challenging patients: Patients with hepato-renal conditions
Dialyzing challenging patients: Patients with hepato-renal conditions Nidyanandh Vadivel MD Medical Director for Living kidney Donor and Pancreas Transplant Programs Swedish Organ Transplant, Seattle Acute
More informationThe MELD Score in Advanced Liver Disease: Association with Clinical Portal Hypertension and Mortality
The MELD Score in Advanced Liver Disease: Association with Clinical Portal Hypertension and Mortality Sammy Saab, 1,2 Carmen Landaverde, 3 Ayman B Ibrahim, 2 Francisco Durazo, 1,2 Steven Han, 1,2 Hasan
More informationIntroduction to Clinical Diagnosis Nephrology
Introduction to Clinical Diagnosis Nephrology I. David Weiner, M.D. C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University of Florida College
More informationLiver Transplantation Evaluation: Objectives
Liver Transplantation Evaluation: Essential Work-Up Curtis K. Argo, MD, MS VGS/ACG Regional Postgraduate Course Williamsburg, VA September 13, 2015 Objectives Discuss determining readiness for transplantation
More informationEDUCATION PRACTICE. Management of Refractory Ascites. Clinical Scenario. The Problem
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:1187 1191 EDUCATION PRACTICE Management of Refractory Ascites ANDRÉS CÁRDENAS and PERE GINÈS Liver Unit, Institute of Digestive Diseases, Hospital Clínic,
More informationAn analysis of tacrolimus-related complications in the first 30 days after liver transplantation
CLINICAL SCIENCE An analysis of tacrolimus-related complications in the first 30 days after liver transplantation Lucas Souto Nacif, André Ibrahim David, Rafael Soares Pinheiro, Marcio Augusto Diniz, Wellington
More informationLiver Transplantation: The End of the Road in Chronic Hepatitis C Infection
University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2012 UMass Center for Clinical and Translational Science Research Retreat
More informationManagement of Ascites and Hepatorenal Syndrome. Florence Wong University of Toronto. June 4, /16/ Gore & Associates: Consultancy
Management of Ascites and Hepatorenal Syndrome Florence Wong University of Toronto June 4, 2016 6/16/2016 1 Disclosures Gore & Associates: Consultancy Sequana Medical: Research Funding Mallinckrodt Pharmaceutical:
More informationThe Management of Ascites & Hepatorenal Syndrome. Florence Wong University of Toronto. Falk Symposium March 14, 2008
The Management of Ascites & Hepatorenal Syndrome Florence Wong University of Toronto Falk Symposium March 14, 2008 Management of Ascites Sodium Restriction Mandatory at all stages of ascites in order to
More informationEvaluation of Renal Profile in Liver Cirrhosis Patients: A Clinical Study
Original article: Evaluation of Renal Profile in Liver Cirrhosis Patients: A Clinical Study Mukesh Agarwal Assistant Professor, Department of General Medicine, Teerthanker Mahaveer Medical College & Research
More informationWhat Is the Real Gain After Liver Transplantation?
LIVER TRANSPLANTATION 15:S1-S5, 9 AASLD/ILTS SYLLABUS What Is the Real Gain After Liver Transplantation? James Neuberger Organ Donation and Transplantation, NHS Blood and Transplant, Bristol, United Kingdom;
More informationNorepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome
Norepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome Disclosure I have no conflicts of interest to disclose Name: Margarita Taburyanskaya Title: PharmD, PGY1 Pharmacy Practice Resident
More informationThe Effect of Residual Renal Function at the Initiation of Dialysis on Patient Survival
ORIGINAL ARTICLE DOI: 10.3904/kjim.2009.24.1.55 The Effect of Residual Renal Function at the Initiation of Dialysis on Patient Survival Seoung Gu Kim 1 and Nam Ho Kim 2 Department of Internal Medicine,
More informationEvaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA
Evaluating HIV Patient for Liver Transplantation Marion G. Peters, MD Professor of Medicine University of California San Francisco USA Slide 2 ESLD and HIV Liver disease has become a major cause of death
More informationTransjugular intrahepatic portal-systemic shunting
Quality of Life in Refractory Ascites: Transjugular Intrahepatic Portal-Systemic Shunting Versus Medical Therapy Mical S. Campbell, 1 Colleen M. Brensinger, 2 Arun J. Sanyal, 3 Chris Gennings, 4 Florence
More informationCKD in Other Organ Transplants
CKD in Other Organ Transplants Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs University of Colorado
More informationManagement of Cirrhosis Related Complications
Management of Cirrhosis Related Complications Ke-Qin Hu, MD, FAASLD Professor of Clinical Medicine Director of Hepatology University of California, Irvine Disclosure I have no disclosure related to this
More informationLong-term prognosis of BK virus-associated nephropathy in kidney transplant recipients
Original Article Kidney Res Clin Pract 37:167-173, 2018(2) pissn: 2211-9132 eissn: 2211-9140 https://doi.org/10.23876/j.krcp.2018.37.2.167 KIDNEY RESEARCH AND CLINICAL PRACTICE Long-term prognosis of BK
More informationPACT module Acute hepatic failure. Intensive Care Training Program Radboud University Medical Centre Nijmegen
PACT module Acute hepatic failure Intensive Care Training Program Radboud University Medical Centre Nijmegen Acute Liver Failure Acute on Chronic Liver Failure Acute loss of hepatocellular function in
More informationSince the beginning of 2002, the priority of adult. Pretransplant MELD Score and Post Liver Transplantation Survival in the UK and Ireland
Pretransplant MELD Score and Post Liver Transplantation Survival in the UK and Ireland Mathew Jacob, 1 Lynn P. Copley, 1 James D. Lewsey, 1,2 Alex Gimson, 3 Giles J. Toogood, 4 Mohamed Rela, 5 and Jan
More informationReview article: hepatorenal syndrome definitions and diagnosis
Aliment Pharmacol Ther 2004; 20 (Suppl. 3): 24 28. Review article: hepatorenal syndrome definitions and diagnosis R. MOREAU & D. LEBREC Laboratoire d Hémodynamique Splanchnique et de Biologie Vasculaire,
More informationThe Yellow Patient. Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust
The Yellow Patient Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust there s a yellow patient in bed 40. It s one of yours. Liver Cirrhosis Why.When.What.etc.
More informationSupplementary Digital Content
Geissler et al: Sirolimus and Hepatocellular Carcinoma in Liver Transplantation Page 1 of 10 Supplementary Digital Content Supplementary Table 1. Surgical procedures used Total Transplant technique Piggy
More informationEND-STAGE RENAL DISEASE ONCE
PAPER Long-term Analysis of Combined Liver and Kidney Transplantation at a Single Center Richard Ruiz, MD; Hiroko Kunitake, MD; Alan H. Wilkinson, MD; Gabriel M. Danovitch, MD; Douglas G. Farmer, MD; Rafik
More informationSpecial Challenges and Co-Morbidities
Special Challenges and Co-Morbidities Renal Disease/ Hypertension/ Diabetes in African-Americans M. Keith Rawlings, MD Medical Director Peabody Health Center AIDS Arms, Inc Dallas, TX Chair, Internal Medicine
More informationBariatric Surgery For Patients With End-Organ Failure
Bariatric Surgery For Patients With End-Organ Failure Arnold D. Salzberg, M.D. Andrew M. Posselt, M.D., PhD Divisions of Transplant and Minimally Invasive Surgery University of California, San Francisco
More informationSERUM CYSTATIN C CONCENTRATION IS A POWERFUL PROGNOSTIC INDICATOR IN PATIENTS WITH CIRRHOTIC ASCITES
SERUM CYSTATIN C CONCENTRATION IS A POWERFUL PROGNOSTIC INDICATOR IN PATIENTS WITH CIRRHOTIC ASCITES YEON SEOK SEO, 1 SOO YOUNG PARK, 2 MOON YOUNG KIM, 3 SANG GYUNE KIM, 4 JUN YONG PARK, 5 HYUNG JOON YIM,
More informationDonor Hypernatremia Influences Outcomes Following Pediatric Liver Transplantation
8 Original Article Donor Hypernatremia Influences Outcomes Following Pediatric Liver Transplantation Neema Kaseje 1 Samuel Lüthold 2 Gilles Mentha 3 Christian Toso 3 Dominique Belli 2 Valérie McLin 2 Barbara
More informationHow and why to measure renal function in patients with liver disease?
ow and why to measure renal function in patients with liver disease? P. Angeli, Dept. of Medicine, Unit of Internal Medicine and epatology (), University of Padova (Italy) pangeli@unipd.it 10th Paris epatology
More informationCombined Orthotopic Heart and Liver Transplantation: The Need for Exception Status Listing 1
SHORT REPORTS Combined Orthotopic Heart and Liver Transplantation: The Need for Exception Status Listing 1 Paige M. Porrett, 1 Shashank S. Desai, 2 Kathleen J. Timmins, 3 Carol R.Twomey, 4 Seema S. Sonnad,
More informationPOST TRANSPLANT OUTCOMES IN PSC
POST TRANSPLANT OUTCOMES IN PSC Kidist K. Yimam, MD Medical Director, Autoimmune Liver Disease Program Division of Hepatology and Liver Transplantation California Pacific Medical Center (CPMC) PSC Partners
More informationHepatorenal Syndrome
Necker Seminars in Nephrology Institut Pasteur Paris, April 22, 2013 Hepatorenal Syndrome Dr. Richard Moreau 1 INSERM U773, Centre de Recherche Biomédicale Bichat-Beaujon CRB3, 2 Université Paris Diderot
More informationPrognostic Importance of the Cause of Renal Failure in Patients With Cirrhosis
GASTROENTEROLOGY 2011;140:488 496 Prognostic Importance of the Cause of Renal Failure in Patients With Cirrhosis MARTA MARTÍN LLAHÍ,*,, MÓNICA GUEVARA,*,, ALDO TORRE,*,, CLAUDIA FAGUNDES,*,, TEA RESTUCCIA,*,,
More informationObjectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives
The Role of the Primary Physician and the Nephrologist in the Management of Chronic Kidney Disease () By Brian Young, M.D. Assistant Clinical Professor of Medicine David Geffen School of Medicine at UCLA
More informationDenver Shunts vs TIPS for Ascites
Denver Shunts vs TIPS for Ascites Hooman Yarmohammadi MD Assistant Professor of Radiology Interventional Radiology & Image Guided Therapies Memorial Sloan-Kettering Cancer Center, New York, USA Hooman
More informationCRAIOVA UNIVERSITY OF MEDICINE AND PHARMACY FACULTY OF MEDICINE ABSTRACT DOCTORAL THESIS
CRAIOVA UNIVERSITY OF MEDICINE AND PHARMACY FACULTY OF MEDICINE ABSTRACT DOCTORAL THESIS RISK FACTORS IN THE EMERGENCE OF POSTOPERATIVE RENAL FAILURE, IMPACT OF TREATMENT WITH ACE INHIBITORS Scientific
More informationTHE KIDNEY AND SLE LUPUS NEPHRITIS
THE KIDNEY AND SLE LUPUS NEPHRITIS JACK WATERMAN DO FACOI 2013 NEPHROLOGY SIR RICHARD BRIGHT TERMINOLOGY RENAL INSUFFICIENCY CKD (CHRONIC KIDNEY DISEASE) ESRD (ENDSTAGE RENAL DISEASE) GLOMERULONEPHRITIS
More informationBK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy
BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent
More informationT here is an increasing discrepancy between the number of
134 LIVER DISEASE MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study F Botta, E Giannini, P Romagnoli,
More informationPredictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
More informationHepatology for the Nonhepatologist
Hepatology for the Nonhepatologist Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Cincinnati, Ohio Learning
More informationAmmonia level at admission predicts in-hospital mortality for patients with alcoholic hepatitis
Gastroenterology Report, 5(3), 2017, 232 236 doi: 10.1093/gastro/gow010 Advance Access Publication Date: 1 May 2016 Original article ORIGINAL ARTICLE Ammonia level at admission predicts in-hospital mortality
More informationSurvival Outcomes Following Liver Transplantation (SOFT) Score: A Novel Method to Predict Patient Survival Following Liver Transplantation
American Journal of Transplantation 2008; 8: 2537 2546 Wiley Periodicals Inc. C 2008 The Authors Journal compilation C 2008 The American Society of Transplantation and the American Society of Transplant
More informationTreating patients with end-stage liver disease: Are we ready? Dr. Mino R. Mitri, M.D., C.M., M.Ed., FRCPC
Treating patients with end-stage liver disease: Are we ready? Dr. Mino R. Mitri, M.D., C.M., M.Ed., FRCPC mino.mitri@ubc.ca No Conflict of Interest 157 patients 157 patients 6 transplanted Criteria Liver
More informationAnaesthetic considerations and peri-operative risks in patients with liver disease
Anaesthetic considerations and peri-operative risks in patients with liver disease Dr. C. K. Pandey Professor & Head Department of Anaesthesiology & Critical Care Medicine Institute of Liver and Biliary
More informationDISEASE LEVEL MEDICAL EVIDENCE PROTOCOL
DISEASE LEVEL MEDICAL EVIDENCE PROTOCOL 1. This Protocol sets out the medical evidence that must be delivered to the Administrator for proof of Disease Level. It is subject to such further and other Protocols
More informationZhao Y Y et al. Ann Intern Med 2012;156:
Zhao Y Y et al. Ann Intern Med 2012;156:560-569 Introduction Fibrates are commonly prescribed to treat dyslipidemia An increase in serum creatinine level after use has been observed in randomized, placebocontrolled
More informationMANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT
MANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT Sherona Bau, ACNP The Pfleger Liver Institute 200 UCLA Medical Plaza, Suite 214 Los Angeles, CA 90095 September 30, 2017 I
More informationHepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of
Hepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of Gastroenterology & Hepatology www.livermd.org HCV in advanced disease In principle
More informationChronic liver failure affects multiple organ systems and
ORIGINAL ARTICLES Model for End-Stage Liver Disease (MELD) Predicts Nontransplant Surgical Mortality in Patients With Cirrhosis Patrick G. Northup, MD,* Ryan C. Wanamaker, MD, Vanessa D. Lee, MD, Reid
More informationInitial approach to ascites
Ascites: Filling and Draining the Water Balloon Common Pathogenesis in Refractory Ascites, Hyponatremia, and Cirrhosis intrahepatic resistance sinusoidal portal hypertension Splanchnic vasodilation (effective
More informationCase Presentation Turki Al-Hussain, MD
Case Presentation Turki Al-Hussain, MD Director, Renal Pathology Chapter Saudi Society of Nephrology & Transplantation Consultant Nephropathologist & Urological Pathologist Department of Pathology & Laboratory
More informationHepatorenal syndrome. Jan T. Kielstein Departent of Nephrology Medical School Hannover
Hepatorenal syndrome Jan T. Kielstein Departent of Nephrology Medical School Hannover Hepatorenal Syndrome 1) History of HRS 2) Pathophysiology of HRS 3) Definition of HRS 4) Clinical presentation of HRS
More informationManagement of Cirrhotic Complications Uncontrolled Ascites. Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University
Management of Cirrhotic Complications Uncontrolled Ascites Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University Topic Definition, pathogenesis Current therapeutic options Experimental treatments
More informationElevated Creatinine in a Patient With Cirrhosis
REVIEW Elevated Creatinine in a Patient With Cirrhosis Heather L. Klavan, M.D., and Brett E. Fortune, M.D., M.S. Elevation in serum creatinine is a common laboratory finding for patients with cirrhosis
More informationWaitlist Priority for Hepatocellular Carcinoma Beyond Milan Criteria: A Potentially Appropriate Decision Without a Structured Approach
American Journal of Transplantation 2014; 14: 79 87 Wiley Periodicals Inc. C Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/ajt.12530
More informationLong-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance
Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,
More informationCombined liver-kidney transplantation (LKT) has
REVIEW ARTICLE Identification of Patients Best Suited for Combined Liver-Kidney Transplantation: Part II. Connie L. Davis, * Thomas A. Gonwa, and Alan H. Wilkinson Liver-kidney transplantation (LKT) should
More informationRECURRENT HEPATITIS C CIRRHOSIS AFTER LIVER TRANSPLANTATION: A NATURAL HISTORY STUDY
RECURRENT HEPATITIS C CIRRHOSIS AFTER LIVER TRANSPLANTATION: A NATURAL HISTORY STUDY By VIRGINIA C. CLARK A THESIS PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT OF
More informationChronic Hepatic Disease
Chronic Hepatic Disease 10 th Leading Cause of Death Liver Functions Energy Metabolism Protein Synthesis Solubilization, Transport, and Storage Protects and Clears drugs, damaged cells Causes of Liver
More informationEarly Allograft Dysfunction After Liver Transplantation Is Associated With Short- and Long-Term Kidney Function Impairment
American Journal of Transplantation 2016; 16: 850 859 Wiley Periodicals Inc. Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/ajt.13527
More informationIntron A Hepatitis C. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.05 Subject: Intron A Hepatitis C Page: 1 of 5 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationCase 1 AND. Treatment of HCV: Pre- vs Post- Transplant. 58 yo male, ESRD/diabetic nephropathy, HD for 3 weeks
Treatment of HCV: Pre- vs Post- Transplant Roy D. Bloom MD Professor of Medicine University of Pennsylvania Roy D. Bloom MD Professor of Medicine Medical Director, Kidney Transplant Program University
More informationContraindications. Indications. Complications. Currently TIPS is considered second or third line therapy for:
Contraindications Absolute Relative Primary prevention variceal bleeding HCC if centrally located Active congestive heart failure Obstruction all hepatic veins Thomas D. Boyer, M.D. University of Arizona
More informationAcute kidney injury (AKI) is the loss of renal
Original Article / Transplantation An effective model for predicting acute kidney injury after liver transplantation Xiao Xu, Qi Ling, Qiang Wei, Jian Wu, Feng Gao, Zeng-Lei He, Lin Zhou and Shu-Sen Zheng
More informationHepatorenal Syndrome: Clinical Considerations
426 Medicine Update 74 Hepatorenal Syndrome: Clinical Considerations VIVEK A SARASWAT, RAVI RATHI BACKGROUND The hepatorenal syndrome (HRS) is a life-threatening form of functional renal failure associated
More informationRenal failure in HCV cirrhosis
IM BOARD REVIEW CHITRA DEEPAK PUNJABI, MD Department of Medicine, Albert Einstein Medical Center, YU KUANG LAI, MD Department of Medicine, Albert Einstein Medical Center, MANJULA BALASUBRAMANIAN, MD Chief,
More informationConflict of interest disclosures. Complications of end stage liver disease. None. The many complications of Cirrhosis. Portal Hypertension.
Complications of end stage liver disease Conflict of interest disclosures None Amir Qamar, MD Instructor of Medicine Brigham and Women s s Hospital Harvard Medical School Boston, MA 02115 The many complications
More informationSteps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV
Overview of Liver Disease Associated With HCV Marion G. Peters, MD John V. Carbone, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco San Francisco,
More informationPrimary sclerosing cholangitis (PSC) is a chronic
Predicting Clinical and Economic Outcomes After Liver Transplantation Using the Mayo Primary Sclerosing Cholangitis Model and Child-Pugh Score Jayant A. Talwalkar, * Eric Seaberg, W. Ray Kim, * and Russell
More informationImproving liver allocation: MELD and PELD
American Journal of Transplantation 24; 4 (Suppl. 9): 114 131 Blackwell Munksgaard Blackwell Munksgaard 24 Improving liver allocation: MELD and PELD Richard B. Freeman Jr a,, Russell H. Wiesner b, John
More informationFinal Report: Update on Prior Living Donors Who Were Subsequently Placed on the Waiting List
OPTN/UNOS Minority Affairs Committee Descriptive Data Request Final Report: Update on Prior Living Donors Who Were Subsequently Placed on the Waiting List Prepared for: Minority Affairs Committee Meeting
More informationRisk factors for consequent kidney impairment and differential impact of liver transplantation on renal function
Nephrol Dial Transplant (2010) 25: 2772 2785 doi: 10.1093/ndt/gfq093 Advance Access publication 5 March 2010 Risk factors for consequent kidney impairment and differential impact of liver transplantation
More informationEffects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis
Gut and Liver, Vol. 11, No. 6, November 2017, pp. 828-834 ORiginal Article Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated
More informationPreoperative Serum Bicarbonate Levels Predict Acute Kidney Iinjry after Cardiac Surgery
International Journal of ChemTech Research CODEN (USA): IJCRGG, ISSN: 0974-4290, ISSN(Online):2455-9555 Vol.11 No.06, pp 203-208, 2018 Preoperative Serum Bicarbonate Levels Predict Acute Kidney Iinjry
More informationAscites is the most common complication of cirrhosis and. Natural History of Patients Hospitalized for Management of Cirrhotic Ascites
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:1385 1394 Natural History of Patients Hospitalized for Management of Cirrhotic Ascites RAMON PLANAS,* SILVIA MONTOLIU,* BELEN BALLESTÉ, MONICA RIVERA, MIREIA
More informationHEPATOrenal Syndrome Type I: Correct Diagnosis = Correct Management
HEPATOrenal Syndrome Type I: Correct Diagnosis = Correct Management Stephen G. M. Wong BSc, BSc(Med), MD, MHSc, FRCPC Associate Professor of Medicine Director, Hepatology Education Section of Hepatology
More informationSimultaneous Liver Kidney Allocation Policy: A Proposal to Optimize Appropriate Utilization of Scarce Resources
American Journal of Transplantation 2016; 16: 758 766 Wiley Periodicals Inc. Special Article Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons doi:
More informationRenal Dysfunction Is the Most Important Independent Predictor of Mortality in Cirrhotic Patients With Spontaneous Bacterial Peritonitis
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:260 265 Renal Dysfunction Is the Most Important Independent Predictor of Mortality in Cirrhotic Patients With Spontaneous Bacterial Peritonitis PUNEETA TANDON*,
More informationThe Effect of HLA Class I (A and B) and Class II (DR) Compatibility on Liver Transplantation Outcomes: An Analysis of the OPTN Database
LIVER TRANSPLANTATION 12:652-658, 2006 ORIGINAL ARTICLE The Effect of HLA Class I (A and B) and Class II (DR) Compatibility on Liver Transplantation Outcomes: An Analysis of the OPTN Database Victor Navarro,
More information1. Discuss the basic pathophysiology of end-stage liver and kidney failure.
TRANSPLANT SURGERY ROTATION (PGY1, 2) A. Medical Knowledge Goal: The resident will achieve a detailed knowledge of the evaluation and treatment of a variety of disease processes. The resident will be exposed
More informationAssessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation
Nephrol Dial Transplant (2002) 17: 1909 1913 Original Article Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new () prediction equation
More informationLife After SVR for Cirrhotic HCV
Life After SVR for Cirrhotic HCV KIM NEWNHAM MN, NP CIRRHOSIS CARE CLINIC UNIVERSITY OF ALBERTA Objectives To review the benefits of HCV clearance in cirrhotic patients To review some of the emerging data
More information